Boston Scientific (NYSE:BSX) Issues FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 3.280-3.320 for the period, compared to the consensus earnings per share estimate of 3.360. The company issued revenue guidance of $21.2 billion-$21.4 billion, compared to the consensus revenue estimate of $21.6 billion. Boston Scientific also updated its Q3 2026 guidance to 0.800-0.820 EPS.

Boston Scientific Stock Up 0.4%

Shares of NYSE:BSX traded up $0.16 during trading on Wednesday, hitting $46.22. The company’s stock had a trading volume of 29,420,356 shares, compared to its average volume of 18,163,301. Boston Scientific has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a market capitalization of $68.70 billion, a PE ratio of 19.33, a P/E/G ratio of 0.87 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The business has a 50 day moving average price of $46.78 and a two-hundred day moving average price of $63.10.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.36 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific will post 3.35 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BSX. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Truist Financial lowered their price target on shares of Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Robert W. Baird set a $70.00 target price on Boston Scientific in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $78.40.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 9,800 shares of company stock worth $554,012 over the last quarter. 0.34% of the stock is currently owned by insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded expectations with adjusted EPS of $0.86 versus the $0.83 consensus and revenue of $5.442 billion versus $5.36 billion. Revenue increased 7.5% year over year, while adjusted EPS rose from $0.75 in the prior-year quarter. Boston Scientific Announces Second-Quarter Results
• Positive Sentiment: Growth was broad-based: Cardiovascular sales increased 8.3%, with particularly strong reported growth in APAC and LACA. U.S. sales rose 6.2%, EMEA 6.1%, APAC 11.2% and LACA 22.4%, while margin expansion also supported the quarterly performance. Boston Scientific Q2 Earnings and Revenue Beat
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase, buying back approximately 40 million shares. It also invested $1.5 billion for a roughly 34% stake in MiRus and an option to acquire its TAVR business, potentially strengthening Boston Scientific’s structural-heart portfolio. Boston Scientific Q2 Revenue Report
• Neutral Sentiment: Boston Scientific received FDA 510(k) clearance for its TruSelect 2.6 Microcatheter, adding a new commercial opportunity, although the immediate financial impact is unclear.
• Negative Sentiment: Management reduced 2026 adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41 and forecast revenue of $21.2-$21.4 billion, below the approximately $21.6 billion consensus. Third-quarter guidance of $0.80-$0.82 EPS and $5.2-$5.3 billion revenue also trails analyst expectations. Boston Scientific Lowers Annual Profit Forecast
• Negative Sentiment: The outlook reduction reflects slower demand for the Watchman heart device, product-growth moderation and increased competition. A global restructuring plan is expected to involve headcount reductions and $700 million-$800 million of costs through 2029, although management targets approximately $500 million in annual savings. Boston Scientific Cuts Outlook Ahead of Restructuring
• Negative Sentiment: UBS lowered its price target to $74 from $95 while retaining a Buy rating, signaling reduced near-term expectations despite confidence in Boston Scientific’s longer-term prospects. UBS Adjusts Boston Scientific Price Target

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BSX. Brighton Jones LLC increased its stake in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Main Street Financial Solutions LLC lifted its stake in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC boosted its holdings in Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC grew its stake in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after purchasing an additional 2,556 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.